Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. Its product pipeline consists of AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. The company has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Period	TotalRevenue
2015-12-31	N/A
2016-12-31	$1.53M
2017-12-31	$181.23M
2018-12-31	$207.74M
2019-12-31	$335.00M
2020-12-31	$295.31M
2021-12-31	$213.58M
2022-12-31	$292.48M
2023-12-31	$194.62M
2024-12-31	$160.18M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AKBA	$1.38	+0.00%	2.35M
3
4
5

Akebia Therapeutics Inc. (AKBA) Revenue History

Revenue Data

Get Akebia Therapeutics Inc. Data in Excel

More AKBA Financial Data